GlassScriptPhysician profile
Stephen R Beaupre
NPI 1619994217
$7,589.70
in general payments reported to CMS, 2019-2025
36 companies · $879 in 2025
The $879 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,316 · 2020: $1,398 · 2021: $1,414 · 2022: $867 · 2023: $937 · 2024: $779 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,594.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,706.58 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,311.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,251.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $421.36 | 2019-2022 | |
| Abbvie INC. | $420.19 | 2019-2025 | Skyrizi, Ubrelvy, Synthroid |
| Amgen INC. | $366.52 | 2019-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.63 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Amarin Pharma, INC. | $270.52 | 2019-2021 | |
| Exact Sciences Corporation | $215.60 | 2023-2025 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $141.48 | 2020-2021 | |
| Genentech USA, INC. | $126.23 | 2019-2022 | |
| Lilly USA, LLC | $116.07 | 2019-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $114.84 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.18 | 2019-2020 | |
| Harmony Biosciences LLC | $81.33 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $62.27 | 2022-2025 | Wegovy |
| Abbott Laboratories | $51.19 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $49.71 | 2023-2024 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $43.08 | 2019 | |
| Melinta Therapeutics, LLC | $42.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $33.46 | 2019-2020 | |
| Boston Scientific Corporation | $33.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $31.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.23 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $30.15 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $25.92 | 2025 | Uptravi, Opsumit |
| Shire North American Group INC | $23.14 | 2019 | |
| Eisai INC. | $19.23 | 2020 | |
| Phathom Pharmaceuticals, INC. | $18.30 | 2024 | Voquezna |
| Sanofi Pasteur INC. | $16.71 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.39 | 2019 | |
| Gilead Sciences, INC. | $14.98 | 2020 | |
| Mylan Specialty L.P. | $12.33 | 2020 | |
| Biodelivery Sciences International, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Beaupre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.